<img width="364" height="150" src="https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header.png" class="attachment-large size-large" alt="Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies" loading="lazy" decoding="async" srcset="https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header.png 364w, https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header-300x124.png 300w" sizes="auto, (max-width: 364px) 100vw, 364px" />

<img width="364" height="150" src="https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header.png" class="attachment-large size-large" alt="Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies" loading="lazy" decoding="async" srcset="https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header.png 364w, https://korecyte.com/wp-content/uploads/2023/07/korecyte-bio-brand-logo-for-header-300x124.png 300w" sizes="auto, (max-width: 364px) 100vw, 364px" />

Grant support

In Q3 2024, Korecyte Innovations Ltd successfully secured an Innovate UK Business Growth grant, supporting the preclinical developments of our KOR101 CAR-T product targeting various solid tumours.